Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
—
—
—
Chandra Bhagat Pharma Ltd is an India-based medicine company. The Company is engaged in the business of marketing pharmaceutical formulation and products in domestic and international markets through its distribution network and sales force under its own brand. It provides a range of products portfolio of a pharmaceutical formulation including injections (ampoules, vials, prefilled syringe, lyophilized vials), tablet, capsules and oral syrup. The Company’s products include for the domestic market mufost, mufost, herzovir, herzovir, clauvmentin, falsun, azap, azocin, chinofen, polodyl, casfungen, cbtaz, nuperazone, nuperazone forte, nuperazone plus, nuperazone 3g, cefzidime tz, cefzidime, cezoneplus, cezone tz, myocholine, klarinton, samcy, dobier s, maxiparine, antacer, cbfos, thionine, thromboparin, meplife combipack, merospect and norepirin.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
Chandra Bhagat Pharma Ltd - 542934 - Board Meeting Intimation for Approval Of Unaudited Result For The Half Year Ended As On September 30, 2024 | Download
Chandra Bhagat Pharma Ltd - 542934 - Board Meeting Intimation for Approval Of Unaudited Result For The Half Year Ended As On September 30, 2024 | Download
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant